Overview
SLU-PP-332 is not a peptide but a small-molecule exercise mimetic — a synthetic agonist of estrogen-related receptors (ERRα, ERRβ, ERRγ), the same nuclear receptors that endurance training activates in muscle. It emerged from Scripps Research and went viral in the biohacking community as exercise in a pill.
In sedentary mice, it increased running endurance by 70% and produced a trained-muscle metabolic profile without any training.
How It Works
ERR receptors are master regulators of mitochondrial biogenesis and oxidative metabolism — the machinery that endurance training builds. SLU-PP-332 activates them directly, shifting muscle toward slow-twitch, fatigue-resistant, fat-burning fiber characteristics.
The mouse data
Treated sedentary mice showed increased mitochondrial density, enhanced fatty acid oxidation, improved glucose tolerance and dramatically better treadmill performance. Crucially, the effects occurred without changes in food intake or activity — pure metabolic reprogramming.
Key Benefits
Endurance enhancement — 70% improvement in mouse treadmill studies.
Fat oxidation — metabolic shift toward burning fat, with reduced fat mass in obese mice.
Metabolic health — improved glucose handling in rodent models.
Exercise-independent adaptation — the entire premise: training adaptations without training.
Side Effects & Considerations
This is a research compound that has never been administered to humans in any published study. Zero human safety data, zero human efficacy data, unknown pharmacokinetics in people.
Reality check
Exercise mimetics have a graveyard of failed translations — the biology of training involves thousands of signals beyond any single receptor. Even if SLU-PP-332 works in humans, it would replicate only the metabolic slice of exercise benefits, not the cardiovascular, skeletal, psychological or social ones. The grey market sells it anyway. Anyone taking it is a pioneer in the least flattering sense: first through the door, first to find out what is behind it.
Dosage protocols
| Protocol | Dosage | Frequency | Duration | Notes |
|---|---|---|---|---|
| Community protocol (anecdotal) | 250-500 mcg | 1-2 times daily | 4-8 weeks | No human studies exist — all dosing is extrapolated from mouse data and is pure speculation. |
Warnings
Never tested in humans. All dosing is speculative extrapolation from rodents. Not approved for any use.